organization · Reporting owner

COLUMN GROUP II, LP

Disclosed activity across 8 companies

Tapewire entity: 84819
SEC CIK: 0001600420

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Gritstone bio, Inc.GRTS · Entity 80946	10% owner	October 02, 2018	October 02, 2018
NGM BIOPHARMACEUTICALS INCNGM · Entity 11997	10% owner	April 05, 2024	April 08, 2024
Oric Pharmaceuticals, Inc.ORIC · Entity 4765	10% owner	November 12, 2021	November 16, 2021
eFFECTOR Therapeutics, Inc.EFTR · Entity 89916	10% owner	August 25, 2021	September 07, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Gritstone bio, Inc.

Report date October 02, 2018 · Filed October 02, 2018

Jointly reported with Column Group II GP, LP, Svennilson Peter, GOEDDEL DAVID V

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	3,102,934	Reported balance After 2018-10-02 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2018-10-02 · Conversion · Acquired 3,102,934 · Balance 3,102,934 F1: The Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F2: The Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F3: The shares are directly held by The Column Group II, LP and indirectly held by The Column Group II GP, LP, the general partner of The Column Group II, LP. The managing partners of The Column Group II GP, LP are David Goeddel and Peter Svennilson. The managing partners of The Column Group II GP, LP may be deemed to have shared voting and investment power with respect to the shares. Each individual managing partner disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
Series A Convertible Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2018-10-02 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2018-10-02 · Conversion · Disposed 2,173,912 · Balance 0 F1: The Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F3: The shares are directly held by The Column Group II, LP and indirectly held by The Column Group II GP, LP, the general partner of The Column Group II, LP. The managing partners of The Column Group II GP, LP are David Goeddel and Peter Svennilson. The managing partners of The Column Group II GP, LP may be deemed to have shared voting and investment power with respect to the shares. Each individual managing partner disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
Series B Convertible Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2018-10-02 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2018-10-02 · Conversion · Disposed 929,022 · Balance 0 F2: The Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F3: The shares are directly held by The Column Group II, LP and indirectly held by The Column Group II GP, LP, the general partner of The Column Group II, LP. The managing partners of The Column Group II GP, LP are David Goeddel and Peter Svennilson. The managing partners of The Column Group II GP, LP may be deemed to have shared voting and investment power with respect to the shares. Each individual managing partner disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F2: The Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F3: The shares are directly held by The Column Group II, LP and indirectly held by The Column Group II GP, LP, the general partner of The Column Group II, LP. The managing partners of The Column Group II GP, LP are David Goeddel and Peter Svennilson. The managing partners of The Column Group II GP, LP may be deemed to have shared voting and investment power with respect to the shares. Each individual managing partner disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.

NGM BIOPHARMACEUTICALS INC

Report date April 05, 2024 · Filed April 08, 2024

Jointly reported with COLUMN GROUP L P, Svennilson Peter, Kutzkey Tim, Ponoi Capital II, LP, Ponoi II Management, LLC, PONOI CAPITAL, LP, Ponoi Management, LLC, Column Group Management LP, Column Group II GP, LP

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnotes	0	Reported balance After 2024-04-05 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2024-04-05 · Disposition to issuer · Disposed 949,862 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F3: The securities were directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG Managing Members"). (cont'd in FN 3) F4: (cont'd from FN 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2024-04-05 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2024-04-05 · Disposition to issuer · Disposed 2,650,177 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F5: The securities were directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG IV GP LLC ("TCG IV LLC") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG IV LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2024-04-05 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2024-04-05 · Disposition to issuer · Disposed 90,442 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F6: The securities were directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG IV LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2024-04-05 transaction · row 5 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 5 · 2024-04-05 · Disposition to issuer · Disposed 858,035 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F8: The securities were directly held by The Column Group III, LP ("TCG III LP"). The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG III GP and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2024-04-05 transaction · row 6 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 6 · 2024-04-05 · Disposition to issuer · Disposed 968,990 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F9: The securities were directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG III GP and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2024-04-05 transaction · row 7 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 7 · 2024-04-05 · Disposition to issuer · Disposed 2,265,758 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F10: The securities were directly held by The Column Group II, LP ("TCG II LP"). TCG II GP is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG II GP are the TCG Managing Partners. The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG II GP and each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2024-04-05 transaction · row 8 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 8 · 2024-04-05 · Disposition to issuer · Disposed 1,298,908 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F11: The securities were directly held by Ponoi Capital, LP ("Ponoi LP"). Ponoi Management, LLC ("Ponoi LLC") is the general partner of Ponoi LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of Ponoi LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Ponoi LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2024-04-05 transaction · row 9 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 9 · 2024-04-05 · Disposition to issuer · Disposed 1,298,908 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F12: The securities were directly held by Ponoi Capital II, LP ("Ponoi II LP"). Ponoi II Management, LLC ("Ponoi II LLC") is the general partner of Ponoi II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of Ponoi II LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Ponoi II LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2024-04-05 transaction · row 10 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 10 · 2024-04-05 · Disposition to issuer · Disposed 100,000 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F13: The securities were directly held by TCG GP. The managing members of TCG GP are the TCG Managing Partners. The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. Each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2024-04-05 transaction · row 11 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 11 · 2024-04-05 · Disposition to issuer · Disposed 100,000 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F14: The securities were directly held by The Column Group Management LP ("TCGM LP"). The managing partners of TCGM LP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2024-04-05 transaction · row 12 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 12 · 2024-04-05 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F15: The securities were owned solely by Tim Kutzkey.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2024-04-05 transaction · row 13 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 13 · 2024-04-05 · Disposition to issuer · Disposed 44,000 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F16: The securities were directly held by Peter Svennilson.
Common StockSEC Table I · non-derivative	IndirectSee footnote	1,000	Reported balance After 2024-04-05 transaction · row 14 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 14 · 2024-04-05 · Other · Acquired 1,000 · Balance 1,000 F17: At the Effective Time, Purchaser merged with and into the Issuer pursuant to Section 251(h) of the Delaware General Corporation Law, with the Issuer surviving as a wholly-owned subsidiary of the Parent. As a result, Parent holds all of the issued and outstanding shares of common stock (equaling 1,000 shares) of the Issuer. TCG LP owns 28.1% of Parent and is the general partner of Parent. Peter Svennilson and Dr. Goeddel are the managing partners of TCG GP, which is the general partner of TCG LP.
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2024-04-05 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 4 · 2024-04-05 · Disposition to issuer · Disposed 11,103,333 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F7: The securities were directly held by The Column Group, LP ("TCG LP").The Column Group GP, LP ("TCG GP") is the general partner of TCG LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG GP are David Goeddel, a member of the Issuer's board of directors and Peter Svennilson (collectively, the "TCG Managing Partners"). The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG GP and each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

Filing footnotes · ownership attribution and instrument terms

F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2)

F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements.

F3: The securities were directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG Managing Members"). (cont'd in FN 3)

F4: (cont'd from FN 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F5: The securities were directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG IV GP LLC ("TCG IV LLC") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG IV LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F6: The securities were directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG IV LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F7: The securities were directly held by The Column Group, LP ("TCG LP").The Column Group GP, LP ("TCG GP") is the general partner of TCG LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG GP are David Goeddel, a member of the Issuer's board of directors and Peter Svennilson (collectively, the "TCG Managing Partners"). The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG GP and each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F8: The securities were directly held by The Column Group III, LP ("TCG III LP"). The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG III GP and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F9: The securities were directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG III GP and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F10: The securities were directly held by The Column Group II, LP ("TCG II LP"). TCG II GP is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG II GP are the TCG Managing Partners. The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG II GP and each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F11: The securities were directly held by Ponoi Capital, LP ("Ponoi LP"). Ponoi Management, LLC ("Ponoi LLC") is the general partner of Ponoi LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of Ponoi LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Ponoi LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F12: The securities were directly held by Ponoi Capital II, LP ("Ponoi II LP"). Ponoi II Management, LLC ("Ponoi II LLC") is the general partner of Ponoi II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of Ponoi II LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Ponoi II LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F13: The securities were directly held by TCG GP. The managing members of TCG GP are the TCG Managing Partners. The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. Each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F14: The securities were directly held by The Column Group Management LP ("TCGM LP"). The managing partners of TCGM LP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F15: The securities were owned solely by Tim Kutzkey.

F16: The securities were directly held by Peter Svennilson.

F17: At the Effective Time, Purchaser merged with and into the Issuer pursuant to Section 251(h) of the Delaware General Corporation Law, with the Issuer surviving as a wholly-owned subsidiary of the Parent. As a result, Parent holds all of the issued and outstanding shares of common stock (equaling 1,000 shares) of the Issuer. TCG LP owns 28.1% of Parent and is the general partner of Parent. Peter Svennilson and Dr. Goeddel are the managing partners of TCG GP, which is the general partner of TCG LP.

Oric Pharmaceuticals, Inc.

Report date November 12, 2021 · Filed November 16, 2021

Jointly reported with Column Group II GP, LP, GOEDDEL DAVID V, Svennilson Peter, Column Group LLC

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	16,625	Reported balance After 2021-11-12 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2021-11-12 · Exercise / conversion · Acquired 16,625 · Balance 16,625 F1: These securities are directly held by Peter Svennilson. Peter Svennilson is a former member of the Issuer's board of directors and previously filed his own Section 16 reports reporting his holdings.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	287,702	Reported balance After 2021-11-16 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2021-11-16 · Other · Acquired 287,702 · Balance 287,702 F4: Represents a change in the form of ownership of TCG II GP by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II LP. F5: The securities are directly held by TCG II GP. The TCG II GP Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG II GP and each individual TCG II GP Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	0	Reported balance After 2021-11-16 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 4 · 2021-11-16 · Other · Disposed 287,702 · Balance 0 F6: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by TCG II GP to its partners. F5: The securities are directly held by TCG II GP. The TCG II GP Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG II GP and each individual TCG II GP Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	86,716	Reported balance After 2021-11-16 transaction · row 5 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 5 · 2021-11-16 · Other · Acquired 86,716 · Balance 86,716 F7: Represents a change in the form of ownership of David Goeddel by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II GP. F8: These securities are directly held by David Goeddel.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	103,341	Reported balance After 2021-11-16 transaction · row 6 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 6 · 2021-11-16 · Other · Acquired 86,716 · Balance 103,341 F9: Represents a change in the form of ownership of Peter Svennilson by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II GP. F1: These securities are directly held by Peter Svennilson. Peter Svennilson is a former member of the Issuer's board of directors and previously filed his own Section 16 reports reporting his holdings.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	74	Reported balance After 2021-11-16 transaction · row 7 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 7 · 2021-11-16 · Other · Acquired 74 · Balance 74 F10: Represents a change in the form of ownership of The Column Group, LLC ("TCG LLC") by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II GP. F11: These securities are directly held by TCG LLC. The managing members of TCG LLC are the TCG II GP Managing Partners and Timothy Kutzkey (collectively, the "TCG LLC Managing Partners"). The TCG LLC Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG LLC and each of the TCG LLC Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
Common StockSEC Table I · non-derivative	Direct	3,568,181	Reported balance After 2021-11-16 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2021-11-16 · Other · Disposed 1,200,000 · Balance 3,568,181 F2: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by The Column Group II, LP ("TCG II LP") to its general and limited partners. F3: The securities are directly held by TCG II LP, and indirectly held by The Column Group II GP, LP ("TCG II GP"), the general partner of TCG II LP. The managing partners of TCG II GP are David Goeddel and Peter Svennilson (collectively, the "TCG II GP Managing Partners"). The TCG II GP Managing Partners may be deemed to have voting and investment power with respect to such shares. TCG II GP and each individual TCG II GP Managing Partner disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2031-06-15	IndirectSee Footnote	0	Reported balance After 2021-11-12 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2021-11-12 · Exercise / conversion · Disposed 16,625 · Balance 0 F12: As of the transaction date, 16,625 of the shares subject to this option have vested. F1: These securities are directly held by Peter Svennilson. Peter Svennilson is a former member of the Issuer's board of directors and previously filed his own Section 16 reports reporting his holdings. F13: The option was granted to Peter Svennilson for his service as a member of the Issuer's board of directors.

Filing footnotes · ownership attribution and instrument terms

F1: These securities are directly held by Peter Svennilson. Peter Svennilson is a former member of the Issuer's board of directors and previously filed his own Section 16 reports reporting his holdings.

F2: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by The Column Group II, LP ("TCG II LP") to its general and limited partners.

F3: The securities are directly held by TCG II LP, and indirectly held by The Column Group II GP, LP ("TCG II GP"), the general partner of TCG II LP. The managing partners of TCG II GP are David Goeddel and Peter Svennilson (collectively, the "TCG II GP Managing Partners"). The TCG II GP Managing Partners may be deemed to have voting and investment power with respect to such shares. TCG II GP and each individual TCG II GP Managing Partner disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

F4: Represents a change in the form of ownership of TCG II GP by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II LP.

F5: The securities are directly held by TCG II GP. The TCG II GP Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG II GP and each individual TCG II GP Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

F6: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by TCG II GP to its partners.

F7: Represents a change in the form of ownership of David Goeddel by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II GP.

F8: These securities are directly held by David Goeddel.

F9: Represents a change in the form of ownership of Peter Svennilson by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II GP.

F10: Represents a change in the form of ownership of The Column Group, LLC ("TCG LLC") by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II GP.

F11: These securities are directly held by TCG LLC. The managing members of TCG LLC are the TCG II GP Managing Partners and Timothy Kutzkey (collectively, the "TCG LLC Managing Partners"). The TCG LLC Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG LLC and each of the TCG LLC Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

F12: As of the transaction date, 16,625 of the shares subject to this option have vested.

F13: The option was granted to Peter Svennilson for his service as a member of the Issuer's board of directors.

eFFECTOR Therapeutics, Inc.

Report date August 25, 2021 · Filed September 07, 2021

Jointly reported with Column Group II GP, LP, Svennilson Peter, GOEDDEL DAVID V

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	4,309,329	Reported balance Holding disclosure · report date 2021-08-25 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 4,309,329 F1: On August 25, 2021, pursuant to that certain Agreement and Plan of Merger, dated as of May 26, 2021 (the "Merger Agreement"), by and among the Issuer (f/k/a Locust Walk Acquisition Corp.), Locust Walk Merger Sub, Inc. ("Merger Sub"), and eFFECTOR Therapeutics, Inc. ("Old eFFECTOR" and "Issuer"), Merger Sub merged with and into Old eFFECTOR with Old eFFECTOR surviving as a wholly owned subsidiary of the Issuer (the "Merger"). Upon consummation of the Merger (the "Effective Time"), each issued and outstanding share of common stock of Old eFFECTOR was automatically cancelled and converted into approximately 0.09657 (the "Exchange Ratio") shares of common stock of the Issuer. F2: Represents 4,109,329 shares of the Issuer's common stock received in connection with the Merger and 200,000 shares of the Issuer's common stock that were acquired in a private placement which closed concurrently with the Merger. F3: The securities are directly held by The Column Group II, LP ("TCG II LP"). The Column Group II GP, LP ("TCG II GP") is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG II GP are David Goeddel and Peter Svennilson (collectively, the "TCG II GP Managing Partners"). The TCG II GP Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG II GP and each of the TCG II GP Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

Filing footnotes · ownership attribution and instrument terms

F1: On August 25, 2021, pursuant to that certain Agreement and Plan of Merger, dated as of May 26, 2021 (the "Merger Agreement"), by and among the Issuer (f/k/a Locust Walk Acquisition Corp.), Locust Walk Merger Sub, Inc. ("Merger Sub"), and eFFECTOR Therapeutics, Inc. ("Old eFFECTOR" and "Issuer"), Merger Sub merged with and into Old eFFECTOR with Old eFFECTOR surviving as a wholly owned subsidiary of the Issuer (the "Merger"). Upon consummation of the Merger (the "Effective Time"), each issued and outstanding share of common stock of Old eFFECTOR was automatically cancelled and converted into approximately 0.09657 (the "Exchange Ratio") shares of common stock of the Issuer.

F2: Represents 4,109,329 shares of the Issuer's common stock received in connection with the Merger and 200,000 shares of the Issuer's common stock that were acquired in a private placement which closed concurrently with the Merger.

F3: The securities are directly held by The Column Group II, LP ("TCG II LP"). The Column Group II GP, LP ("TCG II GP") is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG II GP are David Goeddel and Peter Svennilson (collectively, the "TCG II GP Managing Partners"). The TCG II GP Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG II GP and each of the TCG II GP Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

Past disclosures · reporting ended (4)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Arcus Biosciences, Inc.

Report date March 19, 2018 · Filed March 19, 2018

Jointly reported with Column Group II GP, LP, Ponoi Management, LLC, PONOI CAPITAL, LP, GOEDDEL DAVID V, Svennilson Peter, Kutzkey Tim

Section 16 reporting ended · disclosed 2018-03-19. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,767,676	Reported balance After 2018-03-19 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2018-03-19 · Conversion · Acquired 1,767,676 · Balance 1,767,676 F1: Immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series A, Series B and Series C preferred stock automatically converted into one share of common stock. The Series A, Series B and Series C preferred stock had no expiration date. F2: The securities are directly held by The Column Group II, LP ("TCG II") and indirectly held by The Column Group II GP, LP ("TCG II GP") the general partner of TCG II. TCG II GP has voting and dispositive power with respect to these shares. The individual managing partners of TCG II GP are Peter Svennilson and David Goeddel, who may be deemed to have shared voting, investment and dispositive power with respect to these shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares
Common StockSEC Table I · non-derivative	Direct	2,642,763	Reported balance After 2018-03-19 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2018-03-19 · Conversion · Acquired 875,087 · Balance 2,642,763 F1: Immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series A, Series B and Series C preferred stock automatically converted into one share of common stock. The Series A, Series B and Series C preferred stock had no expiration date. F2: The securities are directly held by The Column Group II, LP ("TCG II") and indirectly held by The Column Group II GP, LP ("TCG II GP") the general partner of TCG II. TCG II GP has voting and dispositive power with respect to these shares. The individual managing partners of TCG II GP are Peter Svennilson and David Goeddel, who may be deemed to have shared voting, investment and dispositive power with respect to these shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares
Common StockSEC Table I · non-derivative	Direct	3,070,423	Reported balance After 2018-03-19 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2018-03-19 · Conversion · Acquired 427,660 · Balance 3,070,423 F1: Immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series A, Series B and Series C preferred stock automatically converted into one share of common stock. The Series A, Series B and Series C preferred stock had no expiration date. F2: The securities are directly held by The Column Group II, LP ("TCG II") and indirectly held by The Column Group II GP, LP ("TCG II GP") the general partner of TCG II. TCG II GP has voting and dispositive power with respect to these shares. The individual managing partners of TCG II GP are Peter Svennilson and David Goeddel, who may be deemed to have shared voting, investment and dispositive power with respect to these shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares
Common StockSEC Table I · non-derivative	Direct	470,427	Reported balance After 2018-03-19 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 4 · 2018-03-19 · Conversion · Acquired 470,427 · Balance 470,427 F1: Immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series A, Series B and Series C preferred stock automatically converted into one share of common stock. The Series A, Series B and Series C preferred stock had no expiration date. F3: The securities are directly held by Ponoi Capital, LP ("Ponoi LP") and indirectly held by Ponoi Management, LLC ("Ponoi LLC") the general partner of Ponoi LP. Ponoi LLC has voting and dispositive power with respect to these shares. The individual managing partners of Ponoi LLC are Peter Svennilson, David Goeddel and Tim Kutzkey, who may be deemed to have shared voting, investment and dispositive power with respect to these shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares.
Series A Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2018-03-19 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2018-03-19 · Conversion · Disposed 1,767,676 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series A, Series B and Series C preferred stock automatically converted into one share of common stock. The Series A, Series B and Series C preferred stock had no expiration date. F2: The securities are directly held by The Column Group II, LP ("TCG II") and indirectly held by The Column Group II GP, LP ("TCG II GP") the general partner of TCG II. TCG II GP has voting and dispositive power with respect to these shares. The individual managing partners of TCG II GP are Peter Svennilson and David Goeddel, who may be deemed to have shared voting, investment and dispositive power with respect to these shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares
Series B Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2018-03-19 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2018-03-19 · Conversion · Disposed 875,087 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series A, Series B and Series C preferred stock automatically converted into one share of common stock. The Series A, Series B and Series C preferred stock had no expiration date. F2: The securities are directly held by The Column Group II, LP ("TCG II") and indirectly held by The Column Group II GP, LP ("TCG II GP") the general partner of TCG II. TCG II GP has voting and dispositive power with respect to these shares. The individual managing partners of TCG II GP are Peter Svennilson and David Goeddel, who may be deemed to have shared voting, investment and dispositive power with respect to these shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares
Series C Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2018-03-19 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2018-03-19 · Conversion · Disposed 427,660 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series A, Series B and Series C preferred stock automatically converted into one share of common stock. The Series A, Series B and Series C preferred stock had no expiration date. F2: The securities are directly held by The Column Group II, LP ("TCG II") and indirectly held by The Column Group II GP, LP ("TCG II GP") the general partner of TCG II. TCG II GP has voting and dispositive power with respect to these shares. The individual managing partners of TCG II GP are Peter Svennilson and David Goeddel, who may be deemed to have shared voting, investment and dispositive power with respect to these shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares
Series C Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2018-03-19 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2018-03-19 · Conversion · Disposed 470,427 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series A, Series B and Series C preferred stock automatically converted into one share of common stock. The Series A, Series B and Series C preferred stock had no expiration date. F3: The securities are directly held by Ponoi Capital, LP ("Ponoi LP") and indirectly held by Ponoi Management, LLC ("Ponoi LLC") the general partner of Ponoi LP. Ponoi LLC has voting and dispositive power with respect to these shares. The individual managing partners of Ponoi LLC are Peter Svennilson, David Goeddel and Tim Kutzkey, who may be deemed to have shared voting, investment and dispositive power with respect to these shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares.

Filing footnotes · ownership attribution and instrument terms

F1: Immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series A, Series B and Series C preferred stock automatically converted into one share of common stock. The Series A, Series B and Series C preferred stock had no expiration date.

F2: The securities are directly held by The Column Group II, LP ("TCG II") and indirectly held by The Column Group II GP, LP ("TCG II GP") the general partner of TCG II. TCG II GP has voting and dispositive power with respect to these shares. The individual managing partners of TCG II GP are Peter Svennilson and David Goeddel, who may be deemed to have shared voting, investment and dispositive power with respect to these shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares

F3: The securities are directly held by Ponoi Capital, LP ("Ponoi LP") and indirectly held by Ponoi Management, LLC ("Ponoi LLC") the general partner of Ponoi LP. Ponoi LLC has voting and dispositive power with respect to these shares. The individual managing partners of Ponoi LLC are Peter Svennilson, David Goeddel and Tim Kutzkey, who may be deemed to have shared voting, investment and dispositive power with respect to these shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares.

IMMUNE DESIGN CORP.

Report date April 02, 2019 · Filed April 02, 2019

Jointly reported with COLUMN GROUP L P, COLUMN GROUP GP, LP, Column Group II GP, LP, PONOI CAPITAL, LP, Ponoi Management, LLC, GOEDDEL DAVID V, Kutzkey Tim, Svennilson Peter

Section 16 reporting ended · disclosed 2019-04-02. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2019-04-02 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2019-04-02 · Other · Disposed 6,642,942 · Balance 0 F1: Includes shares directly held by Ponoi Capital LP ("Ponoi LP"), The Column Group II, LP ("TCG II LP") and The Column Group, LP ("TCG LP"). The Column Group II GP, LP ("TCG II GP"), as the general partner of TCG II LP, has voting and dispositive power with respect to certain of the shares. The Column Group GP, LP ("TCG GP"), as the general partner of TCG LP, has voting and dispositive power with respect to certain of the shares. Ponoi Management, LLC ("Ponoi LLC"), as the general partner of Ponoi LP, has voting and dispositive power with respect to certain of the shares. F2: (cont.) The individual managing partners of both TCG II GP and TCG GP are Peter Svennilson and David Goeddel, who may be deemed to have shared voting and dispositive power with respect to the shares owned by TCG II LP and TCG LP. The individual managing partners of Ponoi LLC are Peter Svennilson, David Goeddel and Tim Kutzkey, who may be deemed to have shared voting and dispositive power with respect to the shares owned by Ponoi LP. Each individual managing partner disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest in such shares.

Filing footnotes · ownership attribution and instrument terms

F1: Includes shares directly held by Ponoi Capital LP ("Ponoi LP"), The Column Group II, LP ("TCG II LP") and The Column Group, LP ("TCG LP"). The Column Group II GP, LP ("TCG II GP"), as the general partner of TCG II LP, has voting and dispositive power with respect to certain of the shares. The Column Group GP, LP ("TCG GP"), as the general partner of TCG LP, has voting and dispositive power with respect to certain of the shares. Ponoi Management, LLC ("Ponoi LLC"), as the general partner of Ponoi LP, has voting and dispositive power with respect to certain of the shares.

F2: (cont.) The individual managing partners of both TCG II GP and TCG GP are Peter Svennilson and David Goeddel, who may be deemed to have shared voting and dispositive power with respect to the shares owned by TCG II LP and TCG LP. The individual managing partners of Ponoi LLC are Peter Svennilson, David Goeddel and Tim Kutzkey, who may be deemed to have shared voting and dispositive power with respect to the shares owned by Ponoi LP. Each individual managing partner disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest in such shares.

Nurix Therapeutics, Inc.

Report date May 07, 2021 · Filed May 07, 2021

Jointly reported with COLUMN GROUP L P, COLUMN GROUP GP, LP, Column Group II GP, LP, PONOI CAPITAL, LP, Ponoi Management, LLC, Ponoi II Management, LLC, Ponoi Capital II, LP, Kutzkey Tim, GOEDDEL DAVID V

Section 16 reporting ended · disclosed 2021-05-07. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,394,333	Reported balance After 2021-05-05 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2021-05-05 · Other · Disposed 2,000,000 · Balance 1,394,333 F1: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by The Column Group, LP ("TCG LP") to its general and limited partners. F2: The securities are directly held by TCG LP, and indirectly held by The Column Group GP, LP ("TCG GP"), the general partner of TCG LP. The managing partners of TCG GP are David Goeddel and Peter Svennilson (the "Managing Partners"). The Managing Partners may be deemed to have voting and investment power with respect to such shares. Each individual Managing Partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	438,338	Reported balance After 2021-05-05 transaction · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · 2021-05-05 · Other · Acquired 438,338 · Balance 438,338 F3: Represents a change in the form of ownership of TCG GP by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG LP. F4: The securities are directly held by TCG GP. The Managing Partners may be deemed to share voting and investment power with respect to such shares. Each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	10,307	Reported balance After 2021-05-05 transaction · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · 2021-05-05 · Other · Acquired 10,307 · Balance 10,307 F5: Represents a change in the form of ownership of Peter Svennilson by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG LP. F6: The securities are directly held by Peter Svennilson
Common StockSEC Table I · non-derivative	IndirectSee Footnote	10,307	Reported balance After 2021-05-05 transaction · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · 2021-05-05 · Other · Acquired 10,307 · Balance 10,307 F7: Represents a change in the form of ownership of David Goeddel by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG LP. F8: The securities are directly held by David Goeddel.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	10,307	Reported balance After 2021-05-05 transaction · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · 2021-05-05 · Other · Acquired 10,307 · Balance 10,307 F9: Represents a change in the form of ownership of Tim Kutzkey by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG LP. F10: The securities are directly held by Tim Kutzkey.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	0	Reported balance After 2021-05-05 transaction · row 6 Holding and transaction disclosures are not merged. 1 source row Row 6 · 2021-05-05 · Other · Disposed 438,338 · Balance 0 F11: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by TCG GP to its general and limited partners. F4: The securities are directly held by TCG GP. The Managing Partners may be deemed to share voting and investment power with respect to such shares. Each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	116,181	Reported balance After 2021-05-05 transaction · row 7 Holding and transaction disclosures are not merged. 1 source row Row 7 · 2021-05-05 · Other · Acquired 105,874 · Balance 116,181 F12: Represents a change in the form of ownership of Peter Svennilson by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG GP. F6: The securities are directly held by Peter Svennilson
Common StockSEC Table I · non-derivative	IndirectSee Footnote	121,554	Reported balance After 2021-05-05 transaction · row 8 Holding and transaction disclosures are not merged. 1 source row Row 8 · 2021-05-05 · Other · Acquired 111,247 · Balance 121,554 F13: Represents a change in the form of ownership of David Goeddel by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG GP. F8: The securities are directly held by David Goeddel.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	40,654	Reported balance After 2021-05-05 transaction · row 9 Holding and transaction disclosures are not merged. 1 source row Row 9 · 2021-05-05 · Other · Acquired 30,347 · Balance 40,654 F14: Represents a change in the form of ownership of Tim Kutzkey by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG GP. F10: The securities are directly held by Tim Kutzkey.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	989,000	Reported balance After 2021-05-05 transaction · row 10 Holding and transaction disclosures are not merged. 1 source row Row 10 · 2021-05-05 · Other · Disposed 1,000,000 · Balance 989,000 F15: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by The Column Group II, LP ("TCG II LP") to its general and limited partners. F16: The securities are directly held by TCG II LP, and indirectly held by The Column Group II GP, LP ("TCG II GP"), the general partner of TCG II LP. The managing partners of TCG II GP are the Managing Partners. The Managing Partners may be deemed to have voting and investment power with respect to such shares. Each individual Managing Partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	49,689	Reported balance After 2021-05-05 transaction · row 11 Holding and transaction disclosures are not merged. 1 source row Row 11 · 2021-05-05 · Other · Acquired 49,689 · Balance 49,689 F17: Represents a change in the form of ownership of TCG II GP by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II LP. F18: The securities are directly held by TCG II GP. The Managing Partners may be deemed to share voting and investment power with respect to such shares. Each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	0	Reported balance After 2021-05-05 transaction · row 12 Holding and transaction disclosures are not merged. 1 source row Row 12 · 2021-05-05 · Other · Disposed 49,689 · Balance 0 F19: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by TCG II GP to its general and limited partners. F18: The securities are directly held by TCG II GP. The Managing Partners may be deemed to share voting and investment power with respect to such shares. Each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	134,010	Reported balance After 2021-05-05 transaction · row 13 Holding and transaction disclosures are not merged. 1 source row Row 13 · 2021-05-05 · Other · Acquired 17,829 · Balance 134,010 F20: Represents a change in the form of ownership of Peter Svennilson by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II GP. F6: The securities are directly held by Peter Svennilson
Common StockSEC Table I · non-derivative	IndirectSee Footnote	139,383	Reported balance After 2021-05-05 transaction · row 14 Holding and transaction disclosures are not merged. 1 source row Row 14 · 2021-05-05 · Other · Acquired 17,829 · Balance 139,383 F21: Represents a change in the form of ownership of David Goeddel by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II GP. F8: The securities are directly held by David Goeddel.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	48,406	Reported balance After 2021-05-05 transaction · row 15 Holding and transaction disclosures are not merged. 1 source row Row 15 · 2021-05-05 · Other · Acquired 7,752 · Balance 48,406 F22: Represents a change in the form of ownership of Tim Kutzkey by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II GP. F10: The securities are directly held by Tim Kutzkey.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	686,274	Reported balance Holding disclosure · report date 2021-05-07 · row 16 Holding and transaction disclosures are not merged. 1 source row Row 16 · Balance 686,274 F23: The securities are directly held by Ponoi Capital, LP ("Ponoi LP"), and indirectly held by Ponoi Management, LLC ("Ponoi LLC"), the general partner of Ponoi LP. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	686,274	Reported balance Holding disclosure · report date 2021-05-07 · row 17 Holding and transaction disclosures are not merged. 1 source row Row 17 · Balance 686,274 F24: The securities are directly held by Ponoi Capital II, LP ("Ponoi II LP"), and indirectly held by Ponoi II Management, LLC ("Ponoi II LLC"), the general partner of Ponoi II LP. The managing partners of Ponoi II LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi II LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by The Column Group, LP ("TCG LP") to its general and limited partners.

F2: The securities are directly held by TCG LP, and indirectly held by The Column Group GP, LP ("TCG GP"), the general partner of TCG LP. The managing partners of TCG GP are David Goeddel and Peter Svennilson (the "Managing Partners"). The Managing Partners may be deemed to have voting and investment power with respect to such shares. Each individual Managing Partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares.

F3: Represents a change in the form of ownership of TCG GP by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG LP.

F4: The securities are directly held by TCG GP. The Managing Partners may be deemed to share voting and investment power with respect to such shares. Each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

F5: Represents a change in the form of ownership of Peter Svennilson by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG LP.

F6: The securities are directly held by Peter Svennilson

F8: The securities are directly held by David Goeddel.

F9: Represents a change in the form of ownership of Tim Kutzkey by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG LP.

F10: The securities are directly held by Tim Kutzkey.

F11: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by TCG GP to its general and limited partners.

F12: Represents a change in the form of ownership of Peter Svennilson by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG GP.

F13: Represents a change in the form of ownership of David Goeddel by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG GP.

F14: Represents a change in the form of ownership of Tim Kutzkey by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG GP.

F15: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by The Column Group II, LP ("TCG II LP") to its general and limited partners.

F16: The securities are directly held by TCG II LP, and indirectly held by The Column Group II GP, LP ("TCG II GP"), the general partner of TCG II LP. The managing partners of TCG II GP are the Managing Partners. The Managing Partners may be deemed to have voting and investment power with respect to such shares. Each individual Managing Partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares.

F17: Represents a change in the form of ownership of TCG II GP by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II LP.

F18: The securities are directly held by TCG II GP. The Managing Partners may be deemed to share voting and investment power with respect to such shares. Each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

F19: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by TCG II GP to its general and limited partners.

F20: Represents a change in the form of ownership of Peter Svennilson by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II GP.

F21: Represents a change in the form of ownership of David Goeddel by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II GP.

F22: Represents a change in the form of ownership of Tim Kutzkey by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II GP.

F23: The securities are directly held by Ponoi Capital, LP ("Ponoi LP"), and indirectly held by Ponoi Management, LLC ("Ponoi LLC"), the general partner of Ponoi LP. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares.

F24: The securities are directly held by Ponoi Capital II, LP ("Ponoi II LP"), and indirectly held by Ponoi II Management, LLC ("Ponoi II LLC"), the general partner of Ponoi II LP. The managing partners of Ponoi II LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi II LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares.

RAPT Therapeutics, Inc.

Report date December 23, 2024 · Filed December 23, 2024

Jointly reported with Column Group IV, LP, Column Group IV-A, LP, Column Group IV GP, LP, TCG IV GP, LLC

Section 16 reporting ended · disclosed 2024-12-23. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	50,000	Reported balance After 2024-12-23 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2024-12-23 · Other · Disposed 1,352,008 · Balance 50,000 F1: On December 23, 2024, The Column Group II, LP ("TCG II LP") and Ponoi Capital, LP ("Ponoi LP") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the "Pre-Funded Warrants"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share. F2: The securities are directly held by TCG II LP. The Column Group II GP, LP ("TCG II GP") is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG II GP are David Goeddel and Peter Svennilson (collectively, the "TCG II GP Managing Partners"). The TCG II GP Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG II GP and each of the TCG II GP Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2024-12-23 transaction · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · 2024-12-23 · Other · Disposed 1,599,417 · Balance 0 F1: On December 23, 2024, The Column Group II, LP ("TCG II LP") and Ponoi Capital, LP ("Ponoi LP") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the "Pre-Funded Warrants"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share. F3: The securities are directly held by Ponoi LP. Ponoi Management, LLC ("Ponoi LLC") is the general partner of Ponoi LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey (collectively, the "Ponoi Managing Partners"). The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Ponoi LLC and the each of the Ponoi Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
Common StockSEC Table I · non-derivative	IndirectSee footnote	1,236,261	Reported balance Holding disclosure · report date 2024-12-23 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 1,236,261 F4: The securities are directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. TCG IV GP LLC ("TCG IV LLC") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are David Goeddel, Peter Svennilson and Tim Kutzkey (collectively, the "TCG IV Managing Members"). The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee footnote	42,189	Reported balance Holding disclosure · report date 2024-12-23 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 42,189 F5: The securities are directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are the TCG IV Managing Members. The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
Common StockSEC Table I · non-derivative	IndirectSee footnote	163	Reported balance Holding disclosure · report date 2024-12-23 · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · Balance 163 F6: The securities are directly held The Column Group LLC ("TCG LLC"). The managing members of TCG LLC are the Ponoi Managing Partners. The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Each of the Ponoi Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
Common StockSEC Table I · non-derivative	IndirectSee footnote	145,401	Reported balance Holding disclosure · report date 2024-12-23 · row 6 Holding and transaction disclosures are not merged. 1 source row Row 6 · Balance 145,401 F7: The securities are directly held by Ponoi Capital II, LP ("Ponoi II LP"). Ponoi II Management, LLC ("Ponoi II LLC") is the general partner of Ponoi II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of Ponoi II LLC are the Ponoi Managing Partners. The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Ponoi II LLC and the each of the Ponoi Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
Warrant (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	1,352,008	Reported balance After 2024-12-23 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2024-12-23 · Other · Acquired 1,352,008 · Balance 1,352,008 F1: On December 23, 2024, The Column Group II, LP ("TCG II LP") and Ponoi Capital, LP ("Ponoi LP") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the "Pre-Funded Warrants"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share. F8: The Pre-Funded Warrant has no expiration date and is exercisable at any time after the date of issuance. Notwithstanding the foregoing, a holder of the Pre-Funded Warrant may not exercise the Pre-Funded Warrant if the holder, together with other persons whose beneficial ownership is aggregated for purposes of Section 13 or Section 16 under the Securities Exchange Act of 1934, as amended, would beneficially own more than 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. F2: The securities are directly held by TCG II LP. The Column Group II GP, LP ("TCG II GP") is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG II GP are David Goeddel and Peter Svennilson (collectively, the "TCG II GP Managing Partners"). The TCG II GP Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG II GP and each of the TCG II GP Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
Warrant (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00	IndirectSee footnote	1,599,417	Reported balance After 2024-12-23 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2024-12-23 · Other · Acquired 1,599,417 · Balance 1,599,417 F1: On December 23, 2024, The Column Group II, LP ("TCG II LP") and Ponoi Capital, LP ("Ponoi LP") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the "Pre-Funded Warrants"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share. F8: The Pre-Funded Warrant has no expiration date and is exercisable at any time after the date of issuance. Notwithstanding the foregoing, a holder of the Pre-Funded Warrant may not exercise the Pre-Funded Warrant if the holder, together with other persons whose beneficial ownership is aggregated for purposes of Section 13 or Section 16 under the Securities Exchange Act of 1934, as amended, would beneficially own more than 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. F3: The securities are directly held by Ponoi LP. Ponoi Management, LLC ("Ponoi LLC") is the general partner of Ponoi LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey (collectively, the "Ponoi Managing Partners"). The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Ponoi LLC and the each of the Ponoi Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

Filing footnotes · ownership attribution and instrument terms

F1: On December 23, 2024, The Column Group II, LP ("TCG II LP") and Ponoi Capital, LP ("Ponoi LP") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the "Pre-Funded Warrants"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share.

F2: The securities are directly held by TCG II LP. The Column Group II GP, LP ("TCG II GP") is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG II GP are David Goeddel and Peter Svennilson (collectively, the "TCG II GP Managing Partners"). The TCG II GP Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG II GP and each of the TCG II GP Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

F3: The securities are directly held by Ponoi LP. Ponoi Management, LLC ("Ponoi LLC") is the general partner of Ponoi LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey (collectively, the "Ponoi Managing Partners"). The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Ponoi LLC and the each of the Ponoi Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

F4: The securities are directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. TCG IV GP LLC ("TCG IV LLC") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are David Goeddel, Peter Svennilson and Tim Kutzkey (collectively, the "TCG IV Managing Members"). The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F5: The securities are directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are the TCG IV Managing Members. The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F6: The securities are directly held The Column Group LLC ("TCG LLC"). The managing members of TCG LLC are the Ponoi Managing Partners. The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Each of the Ponoi Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

F7: The securities are directly held by Ponoi Capital II, LP ("Ponoi II LP"). Ponoi II Management, LLC ("Ponoi II LLC") is the general partner of Ponoi II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of Ponoi II LLC are the Ponoi Managing Partners. The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Ponoi II LLC and the each of the Ponoi Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

F8: The Pre-Funded Warrant has no expiration date and is exercisable at any time after the date of issuance. Notwithstanding the foregoing, a holder of the Pre-Funded Warrant may not exercise the Pre-Funded Warrant if the holder, together with other persons whose beneficial ownership is aggregated for purposes of Section 13 or Section 16 under the Securities Exchange Act of 1934, as amended, would beneficially own more than 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 13, 2020 Filed Aug 17, 2020 19:11 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	19,895	$17.89	$355,921.55	Disclosure SEC source: 0001209191-20-046992 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Column Group Management LP · CIK 0001645340 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,637,579 F1 · shares: Consists of 9,343 shares of Common Stock held directly by The Column Group III, LP ("TCG III LP") and 10,552 shares of Common Stock held directly by The Column Group III-A, LP ("TCG III-A LP"). F2 · ownership.direct: The securities are directly held by TCG III, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
July 30, 2020 Filed Aug 3, 2020 17:54 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	732	$17.99	$13,168.68	Disclosure SEC source: 0001209191-20-044543 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,617,684 F1 · shares: Consists of 344 shares of Common Stock held directly by The Column Group III, LP ("TCG III LP") and 388 shares of Common Stock held directly by The Column Group III-A, LP ("TCG III-A LP"). F2 · ownership.direct: The securities are directly held by TCG III, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
July 28, 2020 Filed Jul 29, 2020 21:49 UTC	Nurix Therapeutics, Inc. NRIX · Entity 1156	ConversionSeries D Preferred Stock · Derivative	686,274	$0.00	$0.00	Disclosure SEC source: 0001209191-20-044007 · doc4.xml · derivative · entry 12 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner · General Partner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner GOEDDEL DAVID V · CIK 0001182464 · Director · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 686,274 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.exercise_date: The Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.expiration_date: The Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F5 · ownership.direct: The securities are directly held by Ponoi Capital II, LP ("Ponoi II LP"), and indirectly held by Ponoi II Management, LLC ("Ponoi II LLC"), the general partner of Ponoi II LP. The managing partners of Ponoi II LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi II LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
July 28, 2020 Filed Jul 29, 2020 21:49 UTC	Nurix Therapeutics, Inc. NRIX · Entity 1156	ConversionSeries D Preferred Stock · Derivative	686,274	$0.00	$0.00	Disclosure SEC source: 0001209191-20-044007 · doc4.xml · derivative · entry 11 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner · General Partner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner GOEDDEL DAVID V · CIK 0001182464 · Director · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 686,274 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.exercise_date: The Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.expiration_date: The Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F4 · ownership.direct: The securities are directly held by Ponoi Capital, LP ("Ponoi LP"), and indirectly held by Ponoi Management, LLC ("Ponoi LLC"), the general partner of Ponoi LP. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
July 28, 2020 Filed Jul 29, 2020 21:49 UTC	Nurix Therapeutics, Inc. NRIX · Entity 1156	ConversionSeries B Preferred Stock · Derivative	1,989,000	$0.00	$0.00	Disclosure SEC source: 0001209191-20-044007 · doc4.xml · derivative · entry 10 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner · General Partner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner GOEDDEL DAVID V · CIK 0001182464 · Director · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,989,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.exercise_date: The Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.expiration_date: The Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F3 · ownership.direct: The securities are directly held by The Column Group II, LP ("TCG II LP"), and indirectly held by The Column Group II GP, LP ("TCG II GP"), the general partner of TCG II LP. The managing partners of TCG II GP are David Goeddel and Peter Svennilson. The managing partners of TCG II GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
July 28, 2020 Filed Jul 29, 2020 21:49 UTC	Nurix Therapeutics, Inc. NRIX · Entity 1156	ConversionSeries B Preferred Stock · Derivative	1,836,000	$0.00	$0.00	Disclosure SEC source: 0001209191-20-044007 · doc4.xml · derivative · entry 9 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner · General Partner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner GOEDDEL DAVID V · CIK 0001182464 · Director · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,836,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.exercise_date: The Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.expiration_date: The Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F2 · ownership.direct: The securities are directly held by The Column Group, LP ("TCG LP"), and indirectly held by The Column Group GP, LP ("TCG GP"), the general partner of TCG LP. The managing partners of TCG GP are David Goeddel and Peter Svennilson. The managing partners of TCG GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
July 28, 2020 Filed Jul 29, 2020 21:49 UTC	Nurix Therapeutics, Inc. NRIX · Entity 1156	ConversionSeries A-2 Preferred Stock · Derivative	875,000	$0.00	$0.00	Disclosure SEC source: 0001209191-20-044007 · doc4.xml · derivative · entry 8 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner · General Partner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner GOEDDEL DAVID V · CIK 0001182464 · Director · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 875,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.exercise_date: The Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.expiration_date: The Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F2 · ownership.direct: The securities are directly held by The Column Group, LP ("TCG LP"), and indirectly held by The Column Group GP, LP ("TCG GP"), the general partner of TCG LP. The managing partners of TCG GP are David Goeddel and Peter Svennilson. The managing partners of TCG GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
July 28, 2020 Filed Jul 29, 2020 21:49 UTC	Nurix Therapeutics, Inc. NRIX · Entity 1156	ConversionSeries A-1 Preferred Stock · Derivative	600,000	$0.00	$0.00	Disclosure SEC source: 0001209191-20-044007 · doc4.xml · derivative · entry 7 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner · General Partner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner GOEDDEL DAVID V · CIK 0001182464 · Director · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 600,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.exercise_date: The Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.expiration_date: The Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F2 · ownership.direct: The securities are directly held by The Column Group, LP ("TCG LP"), and indirectly held by The Column Group GP, LP ("TCG GP"), the general partner of TCG LP. The managing partners of TCG GP are David Goeddel and Peter Svennilson. The managing partners of TCG GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
July 28, 2020 Filed Jul 29, 2020 21:49 UTC	Nurix Therapeutics, Inc. NRIX · Entity 1156	ConversionCommon Stock	686,274	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-044007 · doc4.xml · nonDerivative · entry 6 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner · General Partner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner GOEDDEL DAVID V · CIK 0001182464 · Director · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 686,274 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F5 · ownership.direct: The securities are directly held by Ponoi Capital II, LP ("Ponoi II LP"), and indirectly held by Ponoi II Management, LLC ("Ponoi II LLC"), the general partner of Ponoi II LP. The managing partners of Ponoi II LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi II LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
July 28, 2020 Filed Jul 29, 2020 21:49 UTC	Nurix Therapeutics, Inc. NRIX · Entity 1156	ConversionCommon Stock	686,274	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-044007 · doc4.xml · nonDerivative · entry 5 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner · General Partner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner GOEDDEL DAVID V · CIK 0001182464 · Director · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 686,274 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F4 · ownership.direct: The securities are directly held by Ponoi Capital, LP ("Ponoi LP"), and indirectly held by Ponoi Management, LLC ("Ponoi LLC"), the general partner of Ponoi LP. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
July 28, 2020 Filed Jul 29, 2020 21:49 UTC	Nurix Therapeutics, Inc. NRIX · Entity 1156	ConversionCommon Stock	1,989,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-044007 · doc4.xml · nonDerivative · entry 4 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner · General Partner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner GOEDDEL DAVID V · CIK 0001182464 · Director · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,989,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F3 · ownership.direct: The securities are directly held by The Column Group II, LP ("TCG II LP"), and indirectly held by The Column Group II GP, LP ("TCG II GP"), the general partner of TCG II LP. The managing partners of TCG II GP are David Goeddel and Peter Svennilson. The managing partners of TCG II GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
July 28, 2020 Filed Jul 29, 2020 21:49 UTC	Nurix Therapeutics, Inc. NRIX · Entity 1156	ConversionCommon Stock	1,836,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-044007 · doc4.xml · nonDerivative · entry 3 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner · General Partner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner GOEDDEL DAVID V · CIK 0001182464 · Director · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,394,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F2 · ownership.direct: The securities are directly held by The Column Group, LP ("TCG LP"), and indirectly held by The Column Group GP, LP ("TCG GP"), the general partner of TCG LP. The managing partners of TCG GP are David Goeddel and Peter Svennilson. The managing partners of TCG GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
July 28, 2020 Filed Jul 29, 2020 21:49 UTC	Nurix Therapeutics, Inc. NRIX · Entity 1156	ConversionCommon Stock	875,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-044007 · doc4.xml · nonDerivative · entry 2 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner · General Partner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner GOEDDEL DAVID V · CIK 0001182464 · Director · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,558,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F2 · ownership.direct: The securities are directly held by The Column Group, LP ("TCG LP"), and indirectly held by The Column Group GP, LP ("TCG GP"), the general partner of TCG LP. The managing partners of TCG GP are David Goeddel and Peter Svennilson. The managing partners of TCG GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
July 28, 2020 Filed Jul 29, 2020 21:49 UTC	Nurix Therapeutics, Inc. NRIX · Entity 1156	ConversionCommon Stock	600,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-044007 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner · General Partner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner GOEDDEL DAVID V · CIK 0001182464 · Director · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 683,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F2 · ownership.direct: The securities are directly held by The Column Group, LP ("TCG LP"), and indirectly held by The Column Group GP, LP ("TCG GP"), the general partner of TCG LP. The managing partners of TCG GP are David Goeddel and Peter Svennilson. The managing partners of TCG GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
July 28, 2020 Filed Jul 30, 2020 19:23 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	4,105	$17.99	$73,848.95	Disclosure SEC source: 0001209191-20-044067 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,616,952 F1 · shares: Consists of 1,928 shares of Common Stock held directly by The Column Group III, LP ("TCG III LP") and 2,177 shares of Common Stock held directly by The Column Group III-A, LP ("TCG III-A LP"). F2 · ownership.direct: The securities are directly held by TCG III, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
July 27, 2020 Filed Jul 28, 2020 17:39 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	3,834	$17.99	$68,973.66	Disclosure SEC source: 0001209191-20-043875 · doc4.xml · nonDerivative · entry 2 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,612,847 F4 · shares: Consists of 1,801 shares of Common Stock held directly by TCG III LP and 2,033 shares of Common Stock held directly by TCG III-A LP. F2 · ownership.direct: The securities are directly held by TCG III, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
July 24, 2020 Filed Jul 28, 2020 17:39 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	68,749	$17.93	$1,232,669.57	Disclosure SEC source: 0001209191-20-043875 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,609,013 F1 · shares: Consists of 32,287 shares of Common Stock held directly by The Column Group III, LP ("TCG III LP") and 36,462 shares of Common Stock held directly by The Column Group III-A, LP ("TCG III-A LP"). F2 · ownership.direct: The securities are directly held by TCG III, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
July 22, 2020 Filed Jul 23, 2020 17:39 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	193	$18.00	$3,474.00	Disclosure SEC source: 0001209191-20-043529 · doc4.xml · nonDerivative · entry 2 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Column Group Management LP · CIK 0001645340 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner · General Partner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,540,264 F3 · shares: Consists of 91 shares of Common Stock held directly by TCG III LP and 102 shares of Common Stock held directly by TCG III-A LP. F4 · balance_after: Consists of 723,362 shares of Common Stock held directly by TCG III LP and 816,902 shares of Common Stock held directly by TCG III-A LP. F5 · ownership.direct: The securities are directly held by TCG III LP, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F6 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
July 21, 2020 Filed Jul 23, 2020 17:39 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	Exercise / conversionStock Option (Right to Buy) · Derivative	24,000	$0.00 Strike: $13.35	$0.00	Disclosure SEC source: 0001209191-20-043529 · doc4.xml · derivative · entry 9 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Column Group Management LP · CIK 0001645340 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner · General Partner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,000 shares Expires 2020-08-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F16 · security: Issued pursuant to the Issuer's Amended and Restated 2018 Equity Incentive Plan. F18 · derivative.expiration_date: The option expires 90 days from May 20, 2020, the date Mr. Svennilson's service as a director of the Issuer ceased. F1 · ownership.direct: The securities are directly held by Peter Svennilson, a former director of the Issuer who is a managing partner at The Column Group which invests through The Column Group II, LP ("TCG II LP"), Ponoi Capital, LP ("Ponoi LP"), Ponoi Capital II, LP ("Ponoi II LP"), The Column Group III, LP ("TCG III LP") and The Column Group III-A, LP ("TCG III-A LP," and, together with TCG II LP, Ponoi LP, Ponoi II LP and TCG III LP, the "Funds"), among other entities. Under the partnership agreements of the Funds and his agreement with The Column Group Management, LP ("TCGM LP"), Mr. Svennilson is deemed to hold the securities for the economic benefit of the Funds and TCGM LP. The Funds and their respective general partners, TCGM LP and the individual managing partners of such entities may be deemed indirect beneficial owners of the securities. Such reporting persons disclaim beneficial ownership of the securities except to the extent of their pecuniary interest therein. F2 · ownership.direct: The securities are directly held by Peter Svennilson and certain of the securities are indirectly held by other reporting persons. See footnote 1 and related text. Mr. Svennilson disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
July 21, 2020 Filed Jul 23, 2020 17:39 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	Exercise / conversionCommon Stock	24,000	$13.35	$320,400.00	Disclosure SEC source: 0001209191-20-043529 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Column Group Management LP · CIK 0001645340 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner · General Partner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The securities are directly held by Peter Svennilson, a former director of the Issuer who is a managing partner at The Column Group which invests through The Column Group II, LP ("TCG II LP"), Ponoi Capital, LP ("Ponoi LP"), Ponoi Capital II, LP ("Ponoi II LP"), The Column Group III, LP ("TCG III LP") and The Column Group III-A, LP ("TCG III-A LP," and, together with TCG II LP, Ponoi LP, Ponoi II LP and TCG III LP, the "Funds"), among other entities. Under the partnership agreements of the Funds and his agreement with The Column Group Management, LP ("TCGM LP"), Mr. Svennilson is deemed to hold the securities for the economic benefit of the Funds and TCGM LP. The Funds and their respective general partners, TCGM LP and the individual managing partners of such entities may be deemed indirect beneficial owners of the securities. Such reporting persons disclaim beneficial ownership of the securities except to the extent of their pecuniary interest therein. F2 · ownership.direct: The securities are directly held by Peter Svennilson and certain of the securities are indirectly held by other reporting persons. See footnote 1 and related text. Mr. Svennilson disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
June 18, 2020 Filed Jun 22, 2020 16:31 UTC	RAPT Therapeutics, Inc. RAPT · Entity 62554	OtherStock Option (Right to Buy) · Derivative	22,500	$0.00 Strike: $28.27	$0.00	Disclosure SEC source: 0001209191-20-038191 · doc4.xml · derivative · entry 1 COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner GOEDDEL DAVID V · CIK 0001182464 · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2030-06-17 F1 · derivative.exercise_date: The option shall vest in a series of three successive equal annual installments over the three-year period measured from the date of grant, subject to the continuous service of Peter Svennilson as a director of the Issuer through each applicable vesting date. F2 · ownership.nature: The option was granted to Peter Svennilson, a director of the Issuer who is a managing partner of The Column Group II GP, LP ("TCG II GP"), Ponoi Management, LLC ("Ponoi LLC") and Ponoi II Management, LLC ("Ponoi II LLC"), which are the general partners of The Column Group II, LP ("TCG II LP"), Ponoi Capital, LP ("Ponoi LP") and Ponoi Capital II, LP ("Ponoi II LP," and, together with TCG II LP and Ponoi LP, the "Funds"), respectively. The managing partners of TCG II GP are David Goeddel and Peter Svennilson. The managing partners of Ponoi LLC and Ponoi II LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. Under the partnership agreements of the Funds, Mr. Svennilson is deemed to hold the option for the economic benefit of the Funds. The reporting persons may be deemed indirect beneficial owners of the option. The reporting persons disclaim beneficial ownership of the option except to the extent of their pecuniary interest therein. Read SEC document
May 20, 2020 Filed Jul 23, 2020 17:39 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	GrantStock Option (Right to Buy) · Derivative	16,806	$0.00 Strike: $20.37	$0.00	Disclosure SEC source: 0001209191-20-043529 · doc4.xml · derivative · entry 8 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Column Group Management LP · CIK 0001645340 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner · General Partner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 16,806 Underlying: Common Stock · 16,806 shares Expires 2030-05-19 F16 · security: Issued pursuant to the Issuer's Amended and Restated 2018 Equity Incentive Plan. F19 · derivative.exercise_date: The stock option shall vest in four (4) approximately equal quarterly installments, such that the option shall be fully vested on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day prior to the next Issuer's annual stockholder meeting, subject to Mr. Goeddel's Continuous Service (as defined in the Amended and Restated 2018 Equity Incentive Plan) on each applicable vesting date. F17 · ownership.nature: The securities are directly held by David Goeddel, a director of the Issuer who is a managing partner at The Column Group which invests through the Funds, among other entities. Under the partnership agreements of the Funds and his agreement with TCGM LP, Mr. Goeddel is deemed to hold the securities for the economic benefit of the Funds and TCGM LP. The Funds and their respective general partners, TCGM LP and the individual managing partners of such entities may be deemed indirect beneficial owners of the securities. Such reporting persons disclaim beneficial ownership of the securities except to the extent of their pecuniary interest therein. Read SEC document
April 28, 2020 Filed Apr 28, 2020 17:42 UTC	Oric Pharmaceuticals, Inc. ORIC · Entity 4765	ConversionSeries D Preferred Stock · Derivative	151,515	$0.00	$0.00	Disclosure SEC source: 0001209191-20-025998 · doc4.xml · derivative · entry 8 COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner GOEDDEL DAVID V · CIK 0001182464 · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 151,515 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each of the Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date. F1 · derivative.exercise_date: Each of the Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date. F1 · derivative.expiration_date: Each of the Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date. F2 · ownership.direct: The securities are directly held by The Column Group II, LP ("TCG II LP"), and indirectly held by The Column Group II GP, LP ("TCG II GP"), the general partner of TCG II LP. The managing partners of TCG II GP are David Goeddel and Peter Svennilson. The managing partners of TCG II GP may be deemed to have voting and investment power with respect to such shares. TCG II GP and each individual managing partner disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. Read SEC document
April 28, 2020 Filed Apr 28, 2020 17:42 UTC	Oric Pharmaceuticals, Inc. ORIC · Entity 4765	ConversionSeries C Preferred Stock · Derivative	416,666	$0.00	$0.00	Disclosure SEC source: 0001209191-20-025998 · doc4.xml · derivative · entry 7 COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner GOEDDEL DAVID V · CIK 0001182464 · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 416,666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each of the Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date. F1 · derivative.exercise_date: Each of the Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date. F1 · derivative.expiration_date: Each of the Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date. F2 · ownership.direct: The securities are directly held by The Column Group II, LP ("TCG II LP"), and indirectly held by The Column Group II GP, LP ("TCG II GP"), the general partner of TCG II LP. The managing partners of TCG II GP are David Goeddel and Peter Svennilson. The managing partners of TCG II GP may be deemed to have voting and investment power with respect to such shares. TCG II GP and each individual managing partner disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. Read SEC document
April 28, 2020 Filed Apr 28, 2020 17:42 UTC	Oric Pharmaceuticals, Inc. ORIC · Entity 4765	ConversionSeries B Preferred Stock · Derivative	625,000	$0.00	$0.00	Disclosure SEC source: 0001209191-20-025998 · doc4.xml · derivative · entry 6 COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner GOEDDEL DAVID V · CIK 0001182464 · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 625,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each of the Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date. F1 · derivative.exercise_date: Each of the Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date. F1 · derivative.expiration_date: Each of the Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date. F2 · ownership.direct: The securities are directly held by The Column Group II, LP ("TCG II LP"), and indirectly held by The Column Group II GP, LP ("TCG II GP"), the general partner of TCG II LP. The managing partners of TCG II GP are David Goeddel and Peter Svennilson. The managing partners of TCG II GP may be deemed to have voting and investment power with respect to such shares. TCG II GP and each individual managing partner disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. Read SEC document
April 28, 2020 Filed Apr 28, 2020 17:42 UTC	Oric Pharmaceuticals, Inc. ORIC · Entity 4765	ConversionSeries A Preferred Stock · Derivative	3,500,000	$0.00	$0.00	Disclosure SEC source: 0001209191-20-025998 · doc4.xml · derivative · entry 5 COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner GOEDDEL DAVID V · CIK 0001182464 · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,500,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each of the Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date. F1 · derivative.exercise_date: Each of the Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date. F1 · derivative.expiration_date: Each of the Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date. F2 · ownership.direct: The securities are directly held by The Column Group II, LP ("TCG II LP"), and indirectly held by The Column Group II GP, LP ("TCG II GP"), the general partner of TCG II LP. The managing partners of TCG II GP are David Goeddel and Peter Svennilson. The managing partners of TCG II GP may be deemed to have voting and investment power with respect to such shares. TCG II GP and each individual managing partner disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. Read SEC document
April 28, 2020 Filed Apr 28, 2020 17:42 UTC	Oric Pharmaceuticals, Inc. ORIC · Entity 4765	ConversionCommon Stock	151,515	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-025998 · doc4.xml · nonDerivative · entry 4 COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner GOEDDEL DAVID V · CIK 0001182464 · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,768,181 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each of the Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date. F2 · ownership.direct: The securities are directly held by The Column Group II, LP ("TCG II LP"), and indirectly held by The Column Group II GP, LP ("TCG II GP"), the general partner of TCG II LP. The managing partners of TCG II GP are David Goeddel and Peter Svennilson. The managing partners of TCG II GP may be deemed to have voting and investment power with respect to such shares. TCG II GP and each individual managing partner disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. Read SEC document
April 28, 2020 Filed Apr 28, 2020 17:42 UTC	Oric Pharmaceuticals, Inc. ORIC · Entity 4765	ConversionCommon Stock	416,666	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-025998 · doc4.xml · nonDerivative · entry 3 COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner GOEDDEL DAVID V · CIK 0001182464 · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,616,666 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each of the Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date. F2 · ownership.direct: The securities are directly held by The Column Group II, LP ("TCG II LP"), and indirectly held by The Column Group II GP, LP ("TCG II GP"), the general partner of TCG II LP. The managing partners of TCG II GP are David Goeddel and Peter Svennilson. The managing partners of TCG II GP may be deemed to have voting and investment power with respect to such shares. TCG II GP and each individual managing partner disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. Read SEC document
April 28, 2020 Filed Apr 28, 2020 17:42 UTC	Oric Pharmaceuticals, Inc. ORIC · Entity 4765	ConversionCommon Stock	625,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-025998 · doc4.xml · nonDerivative · entry 2 COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner GOEDDEL DAVID V · CIK 0001182464 · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,200,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each of the Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date. F2 · ownership.direct: The securities are directly held by The Column Group II, LP ("TCG II LP"), and indirectly held by The Column Group II GP, LP ("TCG II GP"), the general partner of TCG II LP. The managing partners of TCG II GP are David Goeddel and Peter Svennilson. The managing partners of TCG II GP may be deemed to have voting and investment power with respect to such shares. TCG II GP and each individual managing partner disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. Read SEC document
April 28, 2020 Filed Apr 28, 2020 17:42 UTC	Oric Pharmaceuticals, Inc. ORIC · Entity 4765	ConversionCommon Stock	3,500,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-025998 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner GOEDDEL DAVID V · CIK 0001182464 · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,575,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each of the Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date. F2 · ownership.direct: The securities are directly held by The Column Group II, LP ("TCG II LP"), and indirectly held by The Column Group II GP, LP ("TCG II GP"), the general partner of TCG II LP. The managing partners of TCG II GP are David Goeddel and Peter Svennilson. The managing partners of TCG II GP may be deemed to have voting and investment power with respect to such shares. TCG II GP and each individual managing partner disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. Read SEC document
April 08, 2020 Filed Apr 9, 2020 17:52 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	112,602	$14.95	$1,683,399.90	Disclosure SEC source: 0001209191-20-024072 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,540,071 F1 · shares: Consists of 52,882 shares of Common Stock held directly by The Column Group III, LP ("TCG III LP") and 59,720 shares of Common Stock held directly by The Column Group III-A, LP ("TCG III-A LP"). F2 · ownership.direct: The securities are directly held by TCG III, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
April 07, 2020 Filed Apr 7, 2020 19:21 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	123,728	$14.38	$1,779,208.64	Disclosure SEC source: 0001209191-20-023862 · doc4.xml · nonDerivative · entry 2 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,427,469 F4 · shares: Consists of 58,107 shares of Common Stock held directly by TCG III LP and 65,621 shares of Common Stock held directly by TCG III-A LP. F2 · ownership.direct: The securities are directly held by TCG III LP, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
April 03, 2020 Filed Apr 7, 2020 19:21 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	14,587	$12.41	$181,024.67	Disclosure SEC source: 0001209191-20-023862 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,303,741 F1 · shares: Consists of 6,851 shares of Common Stock held directly by The Column Group III, LP ("TCG III LP") and 7,736 shares of Common Stock held directly by The Column Group III-A, LP ("TCG III-A LP"). F2 · ownership.direct: The securities are directly held by TCG III LP, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
April 02, 2020 Filed Apr 2, 2020 18:07 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	14,850	$12.40	$184,140.00	Disclosure SEC source: 0001209191-20-022767 · doc4.xml · nonDerivative · entry 3 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,289,154 F4 · shares: Consists of 6,974 shares of Common Stock held directly by TCG III LP and 7,876 shares of Common Stock held directly by TCG III-A LP. F2 · ownership.direct: The securities are directly held by TCG III LP, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
April 01, 2020 Filed Apr 2, 2020 18:07 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	118,067	$12.26	$1,447,501.42	Disclosure SEC source: 0001209191-20-022767 · doc4.xml · nonDerivative · entry 2 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,274,304 F1 · shares: Consists of 55,448 shares of Common Stock held directly by The Column Group III, LP ("TCG III LP") and 62,619 shares of Common Stock held directly by The Column Group III-A, LP ("TCG III-A LP"). F2 · ownership.direct: The securities are directly held by TCG III LP, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
March 31, 2020 Filed Apr 2, 2020 18:07 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	118,067	$12.53	$1,479,379.51	Disclosure SEC source: 0001209191-20-022767 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,156,237 F1 · shares: Consists of 55,448 shares of Common Stock held directly by The Column Group III, LP ("TCG III LP") and 62,619 shares of Common Stock held directly by The Column Group III-A, LP ("TCG III-A LP"). F2 · ownership.direct: The securities are directly held by TCG III LP, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
March 25, 2020 Filed Mar 25, 2020 19:41 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	2,416	$12.49	$30,175.84	Disclosure SEC source: 0001209191-20-021181 · doc4.xml · nonDerivative · entry 3 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,038,170 F5 · shares: Consists of 1,135 shares of Common Stock held directly by TCG III LP and 1,281 shares of Common Stock held directly by TCG III-A LP. F2 · ownership.direct: The securities are directly held by TCG III LP, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
March 24, 2020 Filed Mar 25, 2020 19:41 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	128,377	$12.22	$1,568,766.94	Disclosure SEC source: 0001209191-20-021181 · doc4.xml · nonDerivative · entry 2 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,035,754 F4 · shares: Consists of 60,290 shares of Common Stock held directly by TCG III LP and 68,087 shares of Common Stock held directly by TCG III-A LP. F2 · ownership.direct: The securities are directly held by TCG III LP, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
March 23, 2020 Filed Mar 25, 2020 19:41 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	170,387	$11.63	$1,981,600.81	Disclosure SEC source: 0001209191-20-021181 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 907,377 F1 · shares: Consists of 80,020 shares of Common Stock held directly by The Column Group III, LP ("TCG III LP") and 90,367 shares of Common Stock held directly by The Column Group III-A, LP ("TCG III-A LP"). F2 · ownership.direct: The securities are directly held by TCG III LP, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
March 20, 2020 Filed Mar 23, 2020 17:04 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	143,082	$11.77	$1,684,075.14	Disclosure SEC source: 0001209191-20-020683 · doc4.xml · nonDerivative · entry 2 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 736,990 F4 · shares: Consists of 67,196 shares of Common Stock held directly by TCG III LP and 75,886 shares of Common Stock held directly by TCG III-A LP. F2 · ownership.direct: The securities are directly held by TCG III LP, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
March 19, 2020 Filed Mar 23, 2020 17:04 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	148,464	$11.59	$1,720,697.76	Disclosure SEC source: 0001209191-20-020683 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 593,908 F1 · shares: Consists of 69,724 shares of Common Stock held directly by The Column Group III, LP ("TCG III LP") and 78,740 shares of Common Stock held directly by The Column Group III-A, LP ("TCG III-A LP"). F2 · ownership.direct: The securities are directly held by TCG III LP, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
March 05, 2020 Filed Mar 6, 2020 18:00 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	8,307	$18.00	$149,526.00	Disclosure SEC source: 0001209191-20-017015 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 445,444 F1 · shares: Consists of 3,901 shares of Common Stock held directly by The Column Group III, LP ("TCG III LP") and 4,406 shares of Common Stock held directly by The Column Group III-A, LP ("TCG III-A LP"). F2 · ownership.direct: The securities are directly held by TCG III, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
March 04, 2020 Filed Mar 4, 2020 19:28 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	9,986	$17.96	$179,348.56	Disclosure SEC source: 0001209191-20-016363 · doc4.xml · nonDerivative · entry 3 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 437,137 F5 · shares: Consists of 4,690 shares of Common Stock held directly by TCG III LP and 5,296 shares of Common Stock held directly by TCG III-A LP. F2 · ownership.direct: The securities are directly held by TCG III LP, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
March 03, 2020 Filed Mar 4, 2020 19:28 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	38,758	$17.99	$697,256.42	Disclosure SEC source: 0001209191-20-016363 · doc4.xml · nonDerivative · entry 2 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 427,151 F4 · shares: Consists of 18,202 shares of Common Stock held directly by TCG III LP and 20,556 shares of Common Stock held directly by TCG III-A LP. F2 · ownership.direct: The securities are directly held by TCG III LP, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
March 02, 2020 Filed Mar 4, 2020 19:28 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	14,124	$17.90	$252,819.60	Disclosure SEC source: 0001209191-20-016363 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 388,393 F1 · shares: Consists of 6,633 shares of Common Stock held directly by The Column Group III, LP ("TCG III LP") and 7,491 shares of Common Stock held directly by The Column Group III-A, LP ("TCG III-A LP"). F2 · ownership.direct: The securities are directly held by TCG III LP, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
February 28, 2020 Filed Feb 28, 2020 19:10 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	37,800	$17.91	$676,998.00	Disclosure SEC source: 0001209191-20-014195 · doc4.xml · nonDerivative · entry 3 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 374,269 F5 · shares: Consists of 17,752 shares of Common Stock held directly by TCG III LP and 20,048 shares of Common Stock held directly by TCG III-A LP. F2 · ownership.direct: The securities are directly held by TCG III LP, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
February 27, 2020 Filed Feb 28, 2020 19:10 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	33,896	$17.91	$607,077.36	Disclosure SEC source: 0001209191-20-014195 · doc4.xml · nonDerivative · entry 2 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 336,469 F4 · shares: Consists of 15,919 shares of Common Stock held directly by TCG III LP and 17,977 shares of Common Stock held directly by TCG III-A LP. F2 · ownership.direct: The securities are directly held by TCG III LP, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
February 26, 2020 Filed Feb 28, 2020 19:10 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	3,751	$18.00	$67,518.00	Disclosure SEC source: 0001209191-20-014195 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,573 F1 · shares: Consists of 1,762 shares of Common Stock held directly by The Column Group III, LP ("TCG III LP") and 1,989 shares of Common Stock held directly by The Column Group III-A, LP ("TCG III-A LP"). F2 · ownership.direct: The securities are directly held by TCG III LP, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
February 06, 2020 Filed Feb 10, 2020 16:49 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	44,900	$15.96	$716,604.00	Disclosure SEC source: 0001209191-20-007968 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 298,822 F1 · shares: Consists of 21,087 shares of Common Stock held directly by The Column Group III, LP ("TCG III LP") and 23,813 shares of Common Stock held directly by The Column Group III-A, LP ("TCG III-A LP"). F2 · ownership.direct: The securities are directly held by TCG III, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document
November 11, 2019 Filed Nov 13, 2019 17:27 UTC	NGM BIOPHARMACEUTICALS INC NGM · Entity 11997	PurchaseCommon Stock	15	$12.00	$180.00	Disclosure SEC source: 0001209191-19-056433 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,922 F1 · shares: Consists of 7 shares of Common Stock held directly by The Column Group III, LP ("TCG III LP") and 8 shares of Common Stock held directly by The Column Group III-A, LP ("TCG III-A LP"). F2 · ownership.direct: The securities are directly held by TCG III, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.